Dipraglurant (
INN
Inns are generally establishments or buildings where travelers can seek lodging, and usually, food and drink. Inns are typically located in the country or along a highway; before the advent of motorized transportation they also provided accommo ...
) (code name ADX-48621) is a
negative allosteric modulator of the
mGlu5 receptor which is under development by
Addex Therapeutics for the treatment of
Parkinson's disease
Parkinson's disease (PD), or simply Parkinson's, is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. The symptoms usually emerge slowly, and as the disease worsens, non-motor symptoms becom ...
levodopa-induced dyskinesia (PD-LID).
As of 2014, it is in
phase II Phase II, Phase 2 or Phase Two may refer to:
Media
* Marvel Cinematic Universe: Phase Two, six American superhero films from 2013–2015
* ''Star Trek: Phase II'', an unrealized television series based on the characters of Gene Roddenberry's ''S ...
clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human subject research, human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel v ...
s for this indication.
Addex Therapeutics is also investigating an
extended-release formulation of dipraglurant for the treatment of non-
parkinsonian dystonia.
See also
*
Basimglurant
*
Fenobam
*
Mavoglurant
Mavoglurant (developmental code name AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome and other conditions which has been discontinued. It exerts its effect as an antagonist of the metabotropic glutamate receptor ...
*
Raseglurant
References
External links
Dipraglurant-IR for Parkinson's disease levodopa-induced dyskinesia - Addex TherapeuticsDipraglurant-ER for dystonia - Addex Therapeutics
Imidazopyridines
MGlu5 receptor antagonists
Organofluorides
Alkyne derivatives
{{nervous-system-drug-stub